ArticleAnnals of Saudi medicine
Age, not tumor size, modifies the association between extrathyroidal extension and long-term outcomes in patients with follicular cell-derived thyroid carcinoma.
Article in Annals of Saudi medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFollicular cell-derived thyroid carcinomas (FCTC) are common, with stable mortality rates but significant recurrence risks. Extrathyroidal extension (ETE) affects recurrence risk and staging. The 8th edition of the AJCC/TNM classification excludes microscopic ETE from upstaging but considers gross ETE a significant factor in older patients.
objectiveThis study examines clinical outcomes and disease-free survival (DFS) in FCTC patients with and without ETE, evaluating the modifying effects of age and tumor size on incomplete response risk.
designA single-center retrospective chart review was conducted at King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
settingKing Abdulaziz University Hospital. PATIENTS AND
methodsPatients aged ≥13 years diagnosed from January 2017 to December 2021 with long-term follow-up (≥18 months) were included. Medullary and anaplastic thyroid cancers were excluded. Data on demographics, tumor characteristics, risk stratification, and clinical outcomes were collected. Response to therapy was categorized per the 2015 ATA guidelines. Chi-square and Multivariable analysis assessed interactions between age, tumor size, and ETE in predicting incomplete response. Kaplan-Meier curves visualized survival differences.
main outcome measuresIdentifying the interactions between age and tumor size with ETE to predict the risk of incomplete response to therapy among patients with FCTC. SAMPLE SIZE: 255 patients. The median follow-up duration was 4 years.
resultsPatients with ETE were present in (n=38) 15.7% (8% microscopic, 7% gross). Older patients (≥55 years) with ETE had 26.47-fold higher odds of incomplete response than younger patients. Tumor size independently predicted incomplete response, but its interaction with ETE was not significant. Patients with ETE had a significantly higher incomplete response rate (58% vs. 17%,
conclusionOlder patients with ETE face a markedly higher risk of incomplete response. Tumor size is an independent risk factor in those patients. Management should be stratified by age, advocating more aggressive management for older patients with ETE. LIMITATIONS: Retrospective, and single-center design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.